Abstract:Objective To investigate the clinical significance of brain-derived neurotrophic factor(BDNF) from peripheral serum in patients of sporadic Alzheimer disease(SAD).Methods 43 out-and inpatients of SAD were chosen according to DSM-IV and NINCDS-ADRDA criteria for 'probable AD' from 2004 November to 2005 October,including 18 mild dementia patients,19 moderate dementia patients and 6 severe dementia patients.35 controls were chosen simultaneously in health examinated people.Enzyme-linked immunosorbant assay(ELISA) was used to measure the serum levels of BDNF.Results Gender,age and the level of BDNF showed no significantly difference in AD and control group(χ2= 0.0042,P=0.9483;t=0.38,P=0.7023;t=0.60,P=0.5528,respectively).When SAD patients were divided into 3 groups,no significant differences were observed among mild dementia,moderate dementia,severe dementia and control group(F=0.89,P=0.4526).Conclusions No significant differences were demonstrated in peripheral serum levels of BDNF between SAD patients and controls.Serum levels of BDNF could not be as a candidate marker for clinical diagnosis and could not reflect the severity of dementia.

Clinical Significance of Serum Levels of Brain-derived Neurotrophic Factor in Patients of Sporadic Alzheimer Disease